Kadcyla (ado-trastuzumab emtansine) / ImmunoGen, AbbVie, Roche  >>  Phase 3
Welcome,         Profile    Billing    Logout  

37 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kadcyla (ado-trastuzumab emtansine) / Roche
DynastyBreast01, CTR20233403: A Phase III, Multicenter, Open-label, Randomized Controlled Study to Evaluate DB-1303 Versus Enmetuzumab (T-DM1) in Patients With HER2-Positive Unresectable/Metastatic Breast Cancer Previously Treated with Trastuzumab and Taxanes (Dynasty-Breast01)

Ongoing
3
224
China
Kadcyla (ado-trastuzumab emtansine) - Roche, BNT323 - BioNTech
Yingen Biopharmaceutical (Suzhou) Co., Ltd
HER2-positive unresectable/metastatic breast cancer
 
 
HERB TEA, UMIN000030783: A phase III study comparing T-DM1 with pertuzumab, trastuzumab and docetaxel in elderly patients with advanced stage HER2 positive breast cancer (JCOG1607, study)

Active, not recruiting
3
330
Japan
Herceptin (trastuzumab) - Roche, Perjeta (pertuzumab) - Roche, docetaxel - Generic mfg.
National Cancer Center Hospital
HER2 positive advanced breast cancer
 
 
KL166-Ⅲ-06, CTR20231740: A randomized, open-label, controlled, multicenter phase III trial of A166 for injection versus trastuzumab for injection (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have received prior trastuzumab and taxane therapy

Ongoing
3
357
China
trastuzumab botidotin (A166) - Sichuan Kelun Pharma, Kadcyla (ado-trastuzumab emtansine) - Roche
Sichuan Kelunbotai Biopharmaceutical Co., Ltd
HER2-positive unresectable or metastatic breast cancer
 
 
EMILIA, NCT00829166: A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark SABCS 2015
Nov 2015 - Nov 2015: SABCS 2015
Checkmark In pts with HER2-positive mBC & CNS mets
More
Completed
3
991
Europe, Canada, US, RoW
Trastuzumab emtansine, T-DM1, Trastuzumab-MCC-DM1, RO5304020, Lapatinib, Tykerb, Tyverb, Capecitabine, Xeloda
Hoffmann-La Roche
Breast Cancer
07/12
09/15
TH3RESA, NCT01419197 / 2011-000509-29: A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

Checkmark TH3RESA trial
Jul 2016 - Jul 2016: TH3RESA trial
Checkmark Pathological complete response data for early stage HER2+ breast cancer (neoadjuvant)
Dec 2015 - Dec 2015: Pathological complete response data for early stage HER2+ breast cancer (neoadjuvant)
Checkmark ASCO-BC 2014
More
Completed
3
602
US, Canada, Europe, RoW
Trastuzumab emtansine, Kadcyla, T-DM1, Treatment of physician's choice
Hoffmann-La Roche
Breast Cancer
02/13
08/15
MARIANNE, NCT01120184 / 2009-017905-13: A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer

Checkmark MARIANNE
Aug 2018 - Aug 2018: MARIANNE
Checkmark ASCO 2016 (MARIANNE)
May 2016 - May 2016: ASCO 2016 (MARIANNE)
Checkmark MARIANNE Kadcyla + Perjeta combo trial metastatic breast cancer at ASCO 2015
More
Completed
3
1095
Europe, Canada, Japan, US, RoW
docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin], trastuzumab emtansine
Hoffmann-La Roche, Genentech, Inc.
Breast Cancer
09/14
09/16
KRISTINE, NCT02131064 / 2012-004879-38: A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Checkmark From KRISTINE trial for breast cancer (neo-adjuvant) at ASCO 2016
Jun 2016 - Jun 2016: From KRISTINE trial for breast cancer (neo-adjuvant) at ASCO 2016
Completed
3
444
Canada, US, Europe, RoW
Carboplatin, Docetaxel, Pertuzumab, Perjeta®, RO4368451, Trastuzumab, Herceptin®, Trastuzumab Emtansine, Kadcyla®, RO5304020
Hoffmann-La Roche
Breast Neoplasms
12/15
05/18
YO28405, NCT02144012: A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

Terminated
3
49
RoW
Trastuzumab, Herceptin, Trastuzumab Emtansine, Kadcyla, Docetaxel
Hoffmann-La Roche
Metastatic Breast Cancer
01/16
01/16
KATHERINE, NCT01772472 / 2012-002018-37: A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy

Checkmark Approved for adjuvant therapy of HER2 +ve early breast cancer (based on KATHERINE trial)
Aug 2020 - Aug 2020: Approved for adjuvant therapy of HER2 +ve early breast cancer (based on KATHERINE trial)
Checkmark Approved in South korea for HER2+ve breast cancer with invasive residual lesions after receiving taxane & trastuzumab-based preoperative adjuvant therapy
Aug 2019 - Aug 2019: Approved in South korea for HER2+ve breast cancer with invasive residual lesions after receiving taxane & trastuzumab-based preoperative adjuvant therapy
Checkmark Approved for HER2+ve breast cancer (adjuvant)
More
Completed
3
1486
Europe, Canada, US, RoW
trastuzumab, trastuzumab emtansine
Hoffmann-La Roche, NSABP Foundation Inc, GBG Forschungs GmbH
Breast Cancer
07/18
05/24
BO29919, NCT03084939: Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Completed
3
351
RoW
Trastuzumab Emtansine, Kadcyla, Lapatinib, Capecitabine
Hoffmann-La Roche
Breast Cancer
11/18
03/23
KAITLIN, NCT01966471 / 2012-004902-82: A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Not Appicable Jan 2020 - Dec 2020 : From KAITLIN study for HER2+ve early breast cancer (drug development discontinued)
Not Appicable Jan 2019 - Dec 2020 : Regulatory submission of Perjeta for breast cancer (adjuvant) (drug development discontinued)
Checkmark Of P3 KAITLIN Kadcyla + Perjeta combo trial for operable HER-positive early breast cancer
Jan 2014 - Jan 2014: Of P3 KAITLIN Kadcyla + Perjeta combo trial for operable HER-positive early breast cancer
Completed
3
1846
Europe, Canada, Japan, US, RoW
Trastuzumab Emtansine, Kadcyla, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Paclitaxel, Epirubicin, Doxorubicin, Docetaxel, Cyclophosphamide, 5-Fluorouracil
Hoffmann-La Roche
Breast Cancer
11/19
06/21
KAMILLA, NCT01702571 / 2012-001628-37: A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Completed
3
2185
Europe, Canada, RoW
Trastuzumab Emtansine, RO5304020, T-DM1, Kadcyla
Hoffmann-La Roche
Breast Cancer
07/20
07/20
2019-005017-39: A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast cancer

Not yet recruiting
3
460
Europe, RoW
Tucatinib, ONT-380, ARRY-380, AR00432380, Film-coated tablet, Tukysa
Seagen Inc., Seattle Genetics, Inc., SEATTLE GENETICS, INC., Seagen Inc., Seattle Genetics, Inc., Seagen Inc
Unresectable locally-advanced or metastatic HER2+ breast cancer, Advanced or metastatic breast cancer, Diseases [C] - Cancer [C04]
 
 
IMpassion050, NCT03726879 / 2018-001881-40: A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Hourglass Jan 2021 - Dec 2021 : From Impassion050 trial in combination with doxorubicin, cyclophosphamide followed by paclitaxel, trastuzumab and pertuzumab in early HER2+ breast cancer
Checkmark From IMpassion050 trial for neoadjuvant HER2-positive breast cancer
Jun 2021 - Jun 2021: From IMpassion050 trial for neoadjuvant HER2-positive breast cancer
Completed
3
454
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Placebo, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Neosar, Paclitaxel, Taxol, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Trastuzumab Emtansine, Kadcyla
Hoffmann-La Roche, Chugai Pharmaceutical
Breast Cancer
02/21
08/23
DESTINY-Breast03, NCT03529110 / 2018-000222-61: DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane []

Jan 2023 - Jun 2023: Regulatory decision in China for 2L HER2+ breast cancer (based on DESTINY-Breast03 trial)
Checkmark Launched in South Korea for metastatic HER2-positive breast cancer
Jan 2023 - Jan 2023: Launched in South Korea for metastatic HER2-positive breast cancer
Checkmark Data from DESTINY-Breast03 trial for breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Data from DESTINY-Breast03 trial for breast cancer at SABCS 2022
More
Active, not recruiting
3
524
Europe, Canada, Japan, US, RoW
Trastuzumab deruxtecan (T-DXd), DS-8201a, Ado-trastuzumab emtansine (T-DM1), T-DM1
Daiichi Sankyo, Daiichi Sankyo Co., Ltd., AstraZeneca
Breast Cancer
05/21
07/26
DESTINY-Breast02, NCT03523585 / 2018-000221-31: DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread []

Hourglass Jan 2024 - Jun 2024 : Approval in EU for 3L HER2+ breast cancer (based on DESTINY-Breast02 trial)
Hourglass Jan 2022 - Dec 2022 : Acceptance of regulatory submission in US for pre-treated HER2 breast cancer (based on DESTINY-Breast02 trial)
Checkmark Data from DESTINY-Breast02 trial for HER2-positive, unresectable and/or metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Data from DESTINY-Breast02 trial for HER2-positive, unresectable and/or metastatic breast cancer at SABCS 2022
Checkmark Presentation of primary data from DESTINY-Breast02 trial for HER2 +ve breast cancer
More
Active, not recruiting
3
608
Europe, Japan, US, RoW
Trastuzumab deruxtecan, DS-8201a, T-DXd, Capecitabine, Investigator's Choice Comparative Therapy, Lapatinib, Trastuzumab
Daiichi Sankyo, Daiichi Sankyo Co., Ltd., AstraZeneca
Breast Cancer
06/22
01/26
HER2CLIMB-02, NCT03975647 / 2019-005017-39: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Jan 2024 - Dec 2024: From HER2CLIMB-02 trial for breast cancer
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of HER2CLIMB-02 trial in combination with Kadcyla for breast cancer
Active, not recruiting
3
466
Europe, Canada, Japan, US, RoW
tucatinib, ONT-380, placebo, T-DM1, Kadcyla
Seagen, a wholly owned subsidiary of Pfizer, Seagen Inc., Seattle Genetics, Inc., Seagen Inc
HER2-positive Breast Cancer
06/23
03/29
KL166-III-06, NCT06968585: A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

Active, not recruiting
3
365
RoW
A166, T-DM1
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
HER2-positive Breast Cancer
11/25
03/28
SHR-A1811-305, NCT06126640: A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Recruiting
3
1600
RoW
SHR-A1811, Trastuzumab Emtansine
Jiangsu HengRui Medicine Co., Ltd.
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
04/30
04/32
KATE3, NCT04740918 / 2020-002818-41: A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Terminated
3
96
Europe, Canada, US, RoW
Trastuzumab Emtansine, Kadcyla, T-DM1, RO5304020, Atezolizumab, Tecentriq, RO5541267, MPDL3280A, Placebo
Hoffmann-La Roche
Metastatic Breast Cancer
06/24
06/24
Dynasty-Breast01, NCT06265428: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

Recruiting
3
224
RoW
DB-1303/BNT323, T-DM1
DualityBio Inc., BioNTech SE
HER2-positive Breast Cancer
02/26
02/26
NCT05429684: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Recruiting
3
120
RoW
Trastuzumab, herceptin；Inetetamab, Pertuzumab, Perjeta, Nab paclitaxel, Abraxane, Pyrotinib, SHR-1258, Capecitabine, T-DM1, Trastuzumab Emtansine, Everolimus, RAD001, CDK4/6 inhibitor, Palbociclib；, AI, Letrozole, Anti-PD-1 monoclonal antibody, Sintilimab
First Affiliated Hospital Xi'an Jiaotong University
HER2+ Breast Cancer
02/24
02/24
SYSA1501-009, NCT06313086: DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Recruiting
3
442
RoW
DP303c, trastuzumab emtansine, T -DM1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
HER2-positive Breast Cancer
12/25
02/28
NCT06316531: A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Active, not recruiting
3
274
RoW
BL-M07D1, T-DM1
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
HER2-positive Breast Cancer
05/26
05/26
ProHer, NCT05415215 / 2021-002346-33: A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Completed
3
346
Europe, Canada, RoW
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), PHESGO®, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab, Trastuzumab, and rHuPH20, RO7198574, RG6264, Pertuzumab IV, Perjeta®, RO4368451, Trastuzumab IV, Herceptin®, RO0452317, Trastuzumab Emtansine, Kadcyla®, ado-trastuzumab emtansine, T-DM1, RO5304020, Investigator's Choice of Chemotherapy, Surgery, Radiotherapy
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
11/24
11/25
NCT06846437: JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Recruiting
3
228
RoW
JSKN003, Trastuzumab emtansine (T-DM1)
Shanghai JMT-Bio Inc.
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
10/26
12/28
NCT06830889: A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Recruiting
3
1450
RoW
BL-M07D1, T-DM1
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
HER2-positive Breast Cancer
10/31
12/31
NCT07008976: Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

Recruiting
3
246
RoW
TQB2102 Injection, Trastuzumab Emtansine for Injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
03/28
12/28
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Hourglass Jan 2025 - Dec 2025 : Regulatory submission for HER2+ post-neoadjuvant high-risk breast cancer
Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, GBG Forschungs GmbH, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
Astefania, NCT04873362 / 2020-003681-40: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

Active, not recruiting
3
1188
Europe, US, RoW
Atezolizumab, Tecentriq, RO5541267, MPDL3280A, Trastuzumab Emtansine, Kadcyla, T-DM1, RO5304020, Placebo, Trastuzumab, Herceptin
Hoffmann-La Roche
Breast Cancer
08/28
10/34
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Active, not recruiting
3
1056
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
2011-001462-17: Trial for the optimisation of risk assessment and therapy success predicition in patients with early breast cancer by the use of biomarkers in advance to therapy decission-making to personalize therapies.

Ongoing
2/3
5236
Europe
Epirubicin, Cyclophosphamide, Paclitaxel, Tamoxifen, Anastrozole, Letrozole, Exemestan, trastuzumab emtansine (T-DM1), Trastuzumab, Paclitaxel-Albumin, Gemcitabine, Carboplatin, Pertuzumab, Myocet, RO530-4020/xxx, RO4368451, Concentrate for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Powder for solution for infusion, Kadcyla, Herceptin 150 mg, Abraxane, Perjeta
Westdeutsche Studiengruppe GmbH, Genomic Health , Inc., Roche Pharma AG, Celgene Corp., Amgen, TEVA GmbH, Bayer AG
Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status., Early diagnosed breast cancer at first occurence, with hormone receptor over-expressing tumor and any lymph node involvement (from none to any)., Diseases [C] - Cancer [C04]
 
 
GATSBY, NCT01641939 / 2012-000660-22: A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Terminated
2/3
415
Japan, US, Canada, Europe, RoW
Taxane, trastuzumab emtansine
Hoffmann-La Roche
Gastric Cancer
06/15
04/16
PREDIX HER2, NCT02568839 / 2014-000808-10: Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

Active, not recruiting
2/3
202
Europe
docetaxel + trastuzumab sc + pertuzumab, Herceptin SC, Perjeta, trastuzumab emtansin, Kadcyla
Thomas Hatschek, Dept. of Oncology, Karolinska University Hospital
Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer
02/19
02/29
MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
2/3
350
RoW
MRG002, Trastuzumab Emtansine for Injection
Shanghai Miracogen Inc.
Advanced Breast Cancer, Metastatic Breast Cancer
09/23
10/23
Breast53, NCT05288777: Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

Recruiting
2/3
45
US
T-DM1, trastuzumab emtansine, Capecitabine, xeloda, External Beam Radiation Therapy 0, EBRT, External Beam Radiation Therapy 1
University of Virginia
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
12/28
12/29

Download Options